Welcome to the British Registry for Immunotherapy also known as BRIT.
BRIT is a web-based patient registry that records immunotherapy treatment of patients under the care of BSACI consultants practicing in the UK.
Immunotherapy is a form of specialised treatment that can harness the immune system and reduce symptoms of a wide range of allergic and non-allergic diseases. There is a huge need to understand more about immunotherapy and the effects this has on patient outcomes.
To better understand what the current practises are in the UK
The BRIT registry will enable us to monitor the current immunotherapy practice in the UK by describing the indications for the use of Allergen Immunotherapy (AIT) by both subcutaneous and sublingual immunotherapy routes (also known as SCIT and SLIT). By venom immunotherapy (VIT) and the use of the monoclonal antibody Omalizumab (OMA) for Chronic Spontaneous Urticaria (CSU).
Who can register and add data to the registry
The registry is open for all consultant BSACI members to register their practice(s) for both adult and paediatric patients. Additional healthcare professionals in the practice can register as users under the same practice in order to input data into the registry. Details on how to register can be found here
The objective of the registry
The registry will enable the improvement of patient care by recording serious adverse events that take place during immunotherapy treatment. Should the treatment be discontinued we would record the reasons for the discontinuation of treatment. The registry will help us monitor the efficacy of immunotherapy as well as provide us with an evidence base in which to guide commissioning of services and guideline development.
Management of the registry
The registry is managed by a steering committee consisting of BSACI members and patient organisations (Allergy UK and Anaphylaxis Campaign) it is chaired by Dr Mich Lajeunesse a Paediatric Allergy Consultant at Southampton Children’s Hospital. The committee is responsible for the prudent management of the registry, safety reporting of adverse events as well disseminating the findings from the project both to the medical and scientific community and to patients.
Participant informed consent
Patients who agree to participate are asked to complete a consent form which is then logged with their medical record. The patient will be required to give permission for specific identifiers (which are removed when exporting data) such as; name, DOB, email. Partial identifiers consent include; gender, assignment, ethnicity, the four first digits of their postcode.
Identifiable and commercially sensitive information is held within the registry, which is held on a secure NHS server. BRIT is GDPR compliant and BSACI are the data controllers. Requests for analysis and data export for specific purposes will be reviewed by the steering committee and data generated will contain non identifiable data. No one person or group has access to all of the data.
How is the registry funded?
The registry is funded by unrestricted grants from three companies: AlK Abello, Allergy Therapeutics and Stallergenes.